Your Cart Item
Reports Within

Parameters

Reports Within:

Parameter Include:

Requisites
Measures

Number of red blood cells in the blood

Identifies

Red blood cell disorders

Measures: Number of red blood cells in the blood

Identifies: Red blood cell disorders

60
Mins

Homes

1M
Happy

Customers

4.9
Google

Rating

Certified

Labs

What is the maximum days the report can be obtained for the test

Maximum days the report can be obtained for the test Acute Myeloid Leukemia (AML) MRD Panel By Flowcytometry: 14 days

What are the prerequisites for the test Acute Myeloid Leukemia (AML) MRD Panel By Flowcytometry

  • Peripheral Blood or Bone Marrow sample collected in EDTA tube
  • Patient must have a confirmed diagnosis of Acute Myeloid Leukemia (AML)
  • Test must be ordered by a healthcare provider
  • Patient must not have received recent blood transfusions
  • Patient must not have received recent chemotherapy or radiation therapy

What are the measure values for the test Acute Myeloid Leukemia (AML) MRD Panel By Flowcytometry

  • AML1 (CD56+/CD117+/CD13+/CD33+/CD34+/CD117-)
  • AML2 (CD56+/CD117+/CD13+/CD33+/CD34-/CD117-)
  • AML3 (CD56+/CD117+/CD13+/CD33+/CD34+/CD117+)
  • AML4 (CD56-/CD117-/CD13+/CD33+/CD34+/CD117-)
  • AML5 (CD56-/CD117-/CD13+/CD33+/CD34-/CD117-)

What does this test Acute Myeloid Leukemia (AML) MRD Panel By Flowcytometry identify?

  • This test identifies minimal residual disease (MRD) in patients with Acute Myeloid Leukemia (AML) using flow cytometry.
  • MRD refers to small numbers of leukemia cells that remain in the bone marrow during or after treatment, even when the patient is in remission.
  • Flow cytometry is a technique used to analyze the characteristics of cells in a fluid sample, allowing for the identification of residual leukemia cells.
  • Monitoring MRD levels can help determine the effectiveness of treatment and assess the risk of disease relapse in AML patients.

Why is this test Acute Myeloid Leukemia (AML) MRD Panel By Flowcytometry taken?

Acute Myeloid Leukemia (AML) MRD Panel By Flowcytometry test is taken to monitor the levels of minimal residual disease (MRD) in patients who have been diagnosed with AML. MRD refers to the small number of leukemia cells that may remain in the body during or after treatment, even when the patient is in remission.

This test is important because MRD levels can help doctors determine the effectiveness of treatment and predict the likelihood of relapse. By monitoring MRD levels over time, healthcare providers can make more informed decisions about the patient's treatment plan and adjust it as needed to improve outcomes.

No FAQs available.

Customer Google Rating